Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc. is a U.S.-based discovery and development stage pharmaceutical company focused on novel cancer therapies. The company’s work centers on product candidates designed to improve the effectiveness and delivery of radiation therapy and related oncology treatments.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueInvestigational pharmaceutical products designed to treat cancer and improve standard therapies.
Compounds intended to improve the safety, reliability, or effectiveness of radiation treatment.
Internal development activities supporting preclinical work, trials, and regulatory advancement.
Customers
Shuttle Pharmaceuticals does not sell commercial products broadly; its primary stakeholders are oncology patients indirectly served through hospitals, cancer centers, and physicians if its candidates are approved. In the development stage, the company’s economic “customers” are effectively clinical investigators, research partners, regulators, and future healthcare providers that would adopt its therapies.
Hospitals, cancer centers, and radiation oncology practices that would use approved therapies in patient care.
CROs, trial sites, investigators, and research partners supporting development of Ropidoxuridine and other candidates.
FDA and other oversight bodies, plus academic and clinical collaborators that influence approval and evidence generation.
Strategy
The company’s strategy is to advance a cancer-focused pipeline from discovery into clinical testing, with emphasis on therapies that complement radiation oncology. It also relies on external financing and third-party clinical infrastructure to support development, making capital access and trial execution central to its path forward.
Clinical data is the main value driver for a development-stage oncology company.
Development programs require ongoing external capital before product revenue exists.
A focused therapeutic niche can differentiate the pipeline and support partnering.
Geography
The company is headquartered in the United States and conducts its development activities from a U.S. base. Its business is tied to U.S. clinical, regulatory, and financing markets, with no disclosed commercial revenue geography in the provided materials.
Risks
Shuttle Pharmaceuticals faces the typical risks of a pre-revenue biotech company: clinical failure, regulatory delays, and dependence on external funding. Because the business is centered on a small pipeline and third-party trial execution, setbacks in development or capital access can materially affect its ability to continue operations.
Pipeline value depends on trial results for Ropidoxuridine and related candidates.
Exposure: Lead oncology program
The company has no operating revenue and relies on equity or similar financing.
Exposure: Corporate liquidity and development budget
Drug candidates must satisfy safety and efficacy requirements before commercialization.
Exposure: FDA and clinical pathway
Trials depend on CROs, clinical sites, and vendors outside direct control.
Exposure: Theradex and other service providers
Accounting
Judgemental itemsClinical trial, CRO, and regulatory costs are expensed as incurred and drive operating loss.
Impact: Higher trial activity increases reported R&D expense
Valuation changes can create non-cash gains or losses unrelated to operations.
Impact: Can materially affect net loss and comparability
Embedded features and warrants require periodic fair value remeasurement.
Impact: Can cause volatility in other expense
Equity awards are a meaningful non-cash operating cost for early-stage biotech.
Impact: Raises reported expenses without immediate cash outflow
Similar listed companies
Publicly listed companies with a comparable business focus.
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
RAPT Therapeutics, Inc.
Pharmaceutical Preparations
Ocean Biomedical, Inc.
OCEA · Pharmaceutical Preparations
Intensity Therapeutics, Inc
INTS · Biological Products, (No Diagnostic Substances)
GT Biopharma, Inc.
GTBP · Pharmaceutical Preparations
Cadrenal Therapeutics, Inc.
CVKD · Pharmaceutical Preparations
Last updated: 24/09/2026